Inlyta® is the commercial brand name of Axitinib Tablets, an orally selective multi-target VEGFR tyrosine kinase inhibitor developed by Pfizer. It suppresses vascular endothelial growth factor receptor to block tumor angiogenesis and inhibit renal carcinoma proliferation.

Main Indications
Treatment of advanced renal cell carcinoma after failure of prior systemic first-line therapy.

Common Side Effects
Common mild adverse reactions: Hypertension, diarrhea, fatigue, hoarseness and hand-foot skin reaction.
Laboratory abnormalities: Transient elevation of liver enzymes and decreased blood cell counts.
Severe but manageable risks: Severe hemorrhage, gastrointestinal perforation and hypersensitivity reactions.

Approval Status in China
Inlyta® (Axitinib Tablets, 5mg) was officially approved for marketing in China in 2015. It is currently a prescription anti-tumor drug included in China’s Category B medical insurance.

Buy Inlyta (Axitinib Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.